methylphenidate has been researched along with Genetic Predisposition in 19 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Excerpt | Relevance | Reference |
---|---|---|
"Narcolepsy is an emblematic, unique disease within sleep disorders that is characterised by excessive daytime sleepiness, cataplexy and other abnormal manifestations of REM sleep." | 2.48 | [Diagnostic and therapeutic update in narcolepsy]. ( Santamaria-Cano, J, 2012) |
"Although dyslexia is widely diagnosed and affects a very important portion of the childhood population, a conceptual definition of the condition is still lacking." | 1.35 | [Dyslexia: a disease, a disorder or something else?]. ( Artigas-Pallarés, J, 2009) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 8 (42.11) | 29.6817 |
2010's | 11 (57.89) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Akay, AP | 1 |
Kaya, GÇ | 1 |
Kose, S | 1 |
Yazıcıoğlu, ÇE | 1 |
Erkuran, HÖ | 1 |
Güney, SA | 1 |
Oğuz, K | 1 |
Keskin, D | 1 |
Baykara, B | 1 |
Emiroğlu, Nİ | 1 |
Eren, MŞ | 1 |
Kızıldağ, S | 1 |
Ertay, T | 1 |
Özsoylu, D | 1 |
Miral, S | 1 |
Durak, H | 1 |
Gönül, AS | 1 |
Rohde, LA | 1 |
Tarver, J | 1 |
Daley, D | 1 |
Sayal, K | 1 |
Eyre, HA | 1 |
Eskin, A | 1 |
Nelson, SF | 1 |
St Cyr, NM | 1 |
Siddarth, P | 1 |
Baune, BT | 1 |
Lavretsky, H | 1 |
Sengupta, S | 1 |
Grizenko, N | 2 |
Schmitz, N | 1 |
Schwartz, G | 1 |
Bellingham, J | 1 |
Polotskaia, A | 1 |
Stepanian, MT | 1 |
Goto, Y | 1 |
Grace, AA | 1 |
Joober, R | 2 |
Yan, TC | 1 |
McQuillin, A | 1 |
Thapar, A | 1 |
Asherson, P | 1 |
Hunt, SP | 1 |
Stanford, SC | 1 |
Gurling, H | 1 |
Artigas-Pallarés, J | 1 |
Banaschewski, T | 1 |
Konrad, K | 1 |
Rothenberger, A | 1 |
Hebebrand, J | 1 |
Won, H | 1 |
Mah, W | 1 |
Kim, E | 2 |
Kim, JW | 3 |
Hahm, EK | 1 |
Kim, MH | 1 |
Cho, S | 1 |
Kim, J | 1 |
Jang, H | 1 |
Cho, SC | 3 |
Kim, BN | 3 |
Shin, MS | 3 |
Seo, J | 1 |
Jeong, J | 1 |
Choi, SY | 1 |
Kim, D | 1 |
Kang, C | 1 |
Jain, M | 1 |
Vélez, JI | 1 |
Acosta, MT | 1 |
Palacio, LG | 1 |
Balog, J | 1 |
Roessler, E | 1 |
Pineda, D | 1 |
Londoño, AC | 1 |
Palacio, JD | 1 |
Arbelaez, A | 1 |
Lopera, F | 1 |
Elia, J | 1 |
Hakonarson, H | 1 |
Seitz, C | 1 |
Freitag, CM | 1 |
Palmason, H | 1 |
Meyer, J | 1 |
Romanos, M | 1 |
Walitza, S | 1 |
Hemminger, U | 1 |
Warnke, A | 1 |
Romanos, J | 1 |
Renner, T | 1 |
Jacob, C | 1 |
Lesch, KP | 1 |
Swanson, J | 1 |
Castellanos, FX | 1 |
Bailey-Wilson, JE | 1 |
Arcos-Burgos, M | 1 |
Muenke, M | 1 |
Cummins, TD | 1 |
Bellgrove, MA | 1 |
Hong, SB | 2 |
Song, SH | 1 |
Kim, JH | 1 |
Son, JW | 1 |
Shin, YM | 1 |
Chung, US | 1 |
Han, DH | 1 |
Trujillo-Orrego, N | 1 |
Ibáñez, A | 1 |
Pineda, DA | 1 |
Park, S | 1 |
Yang, YH | 1 |
Park, MH | 1 |
Yoo, HJ | 1 |
Santamaria-Cano, J | 1 |
Fortier, MÈ | 1 |
Sengupta, SM | 1 |
Choudhry, Z | 1 |
Thakur, G | 1 |
Abramowicz, MJ | 1 |
Van Haecke, P | 1 |
Demedts, M | 1 |
Delcroix, M | 1 |
Siesser, WB | 1 |
Zhao, J | 1 |
Miller, LR | 1 |
Cheng, SY | 1 |
McDonald, MP | 1 |
Faraone, SV | 1 |
Biederman, J | 1 |
Spencer, T | 1 |
Wilens, T | 1 |
Seidman, LJ | 1 |
Mick, E | 1 |
Doyle, AE | 1 |
Ripley, A | 1 |
Denney, CB | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Use of Methylphenidate to Improve Clinical Outcomes in Geriatric Depression: A Double-blind Placebo-Controlled Trial of Methylphenidate (Ritalin) Augmentation of Citalopram (Celexa) in Depressed Elderly Patients[NCT00602290] | Phase 4 | 181 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
Candidate Gene Screening for 6-14 Year Old Patients With ADHD (Attention Deficit/ Hyperactivity Disorder)[NCT03018574] | 100 participants (Actual) | Observational | 2016-05-31 | Completed | |||
An Open-label Prospective Trial to Evaluate Functional Outcomes of OROS Methylphenidate in Children With ADHD (FOSCO)[NCT01012622] | Phase 4 | 142 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Hamilton Depression Rating Scale (HDRS) is a 24-item depression scale and the total score is summed with a minimum score=0 and maximum score=76. There are no subscales and the higher values represent a worse outcome. Outcomes are measured and defined as follows: 1) Response will be defined as HDRS scores of 10 or less; 2) Sustained response will be defined as maintained response at week 16; 4) Remission will be defined as HDRS scores of 6 or less. (NCT00602290)
Timeframe: Maintained response measured at Week 16
Intervention | units on a scale (Mean) |
---|---|
1 - Citalopram + Placebo | 18.3 |
2 - Methylphenidate + Placebo | 18.7 |
3 - Methylphenidate + Citalopram | 19.8 |
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) is a 16 item self-administered questionnaire that captures life satisfaction over the past week. Each question is rated on a 5 point scale from 1 (Very Poor) to 5 (Very Good). The total score is reported for items 1-14. The minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70 with higher values representing a better outcome. (NCT00602290)
Timeframe: Measured at Baseline and Week 16
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline | Week 16 | |
1 - Citalopram + Placebo | 45.50 | 54.45 |
2 - Methylphenidate + Placebo | 47.06 | 53.54 |
3 - Methylphenidate + Citalopram | 47.52 | 57.79 |
"Remission is defined by all of the following criteria; 1) K-ARS Total score of 18 or less. 2) Very much improved or Much improved in CGI-I. K-ARS total score ranges from 0 (no symptoms) to 54 (highly symptomatic), higher score indicates worsening of condition. CGI-I is a 7-point scale ranging from 1 to 7, where 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse, higher score indicates worsening of condition." (NCT01012622)
Timeframe: Week 12
Intervention | participants (Number) |
---|---|
Osmotic Release Oral System (OROS) Methylphenidate HCL | 99 |
Response is defined as at least 25 percent (%) decrease in total score of K-ARS compared to baseline. K-ARS measures the 18 symptoms based on DSM-IV (1994). Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often), whereas the rating of 2 points or more was regarded as abnormal. Total scores range from 0 (no symptoms) to 54 (highly symptomatic), higher score indicates worsening of condition. (NCT01012622)
Timeframe: Week 12
Intervention | participants (Number) |
---|---|
Osmotic Release Oral System (OROS) Methylphenidate HCL | 118 |
APRS scale measures four factors in elementary school children such as learning ability, academic performance, impulse control, and social withdrawal. In particular, it is excellent in assessing drug effect on the academic performance not measured by other scales. Score ranges from 19 to 95, higher score means better academic performance. (NCT01012622)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline | Change at Week 12 | |
Osmotic Release Oral System (OROS) Methylphenidate HCL | 55.46 | 7.40 |
CAT was developed to properly reflect brain function in childhood. It provided measurement of simple auditory selective attention in terms of omission (number of missing response to target stimulus [0-150], higher score indicate greater omission), false alarm (number of response to non-target stimulus [0-150], higher score indicate greater false alarm), response mean (average time spent to response to target stimulus [200-1100, low score means faster response to target stimulus]), Response (consistency of response time to target stimulus [30-650, Low score means good consistency of response]). (NCT01012622)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Omission:Baseline | Omission:Change at Week 12 | False alarm:Baseline | False alarm:Change at Week 12 | Response mean:Baseline | Response mean:Change at Week 12 | Response:Baseline | Response:Change at Week 12 | |
Osmotic Release Oral System (OROS) Methylphenidate HCL | 10.31 | -6.27 | 12.07 | -3.61 | 623.95 | -55.34 | 265.69 | -63.76 |
Beck Depression Inventory (BDI) consisted of 21 items for measuring the subjective severity of depression and emotional, cognitive, motivational, physiological symptoms of depression. Each question has a set of 4 possible answer choices, ranging in intensity, each answer being scored on a scale value of 0 (no symptom) to 3 (the most severe symptom). Accordingly, the total score ranges from 0 (no symptom) to 63 (the most severe symptom) for 21 questions. (NCT01012622)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline | Change at Week 12 | |
Osmotic Release Oral System (OROS) Methylphenidate HCL | 11.69 | -1.89 |
CHIP was designed to assess the physical, psychological health conditions and functional well-being of children. The instrument has sub-domains such satisfaction (11 items) ranges from 0 to 44, stability (22 items) ranges from 0 to 88, elasticity (19 items) ranges from 0 to 76, risk aversion (14 items) ranges from 0 to 56, achievement (10 items) ranges from 0 to 40. Good health is in the range from 44 to 56 points for all sub-domains. A score of 43 or below indicates poor health in that domain. A score of 57 or higher indicates excellent health. The total score is an average of the scores for the 5 domains and ranges from 0 to 304. Higher total score indicates better health. (NCT01012622)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Score:Baseline (n=126) | Total Score:Change at Week 12 (n=126) | Satisfaction:Baseline (n=132) | Satisfaction:Change at Week 12 (n=132) | Stability:Baseline (n=129) | Stability:Change at Week 12 (n=129) | Elasticity:Baseline (n=132) | Elasticity:Change at Week 12 (n=132) | Risk aversion:Baseline (n=132) | Risk aversion:Change at Week 12 (n=132) | Achievement:Baseline (n=133) | Achievement:Change at Week 12 (n=133) | |
Osmotic Release Oral System (OROS) Methylphenidate HCL | 207.85 | 18.08 | 26.17 | 2.27 | 82.13 | 4.47 | 38.30 | 2.53 | 40.67 | 5.73 | 21.00 | 2.45 |
"The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to Normal, not at all ill and a rating of 7 is equivalent to Among the most extremely ill participants. Higher change scores indicate worsening." (NCT01012622)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline | Change at Week 12 | |
Osmotic Release Oral System (OROS) Methylphenidate HCL | 5.14 | -2.51 |
CAT was developed to properly reflect brain function in childhood. It provided measurement of simple divided attention in terms of omission(number of missing response to target stimulus[0-150], higher score indicate greater omission), false alarm(number of response to non-target stimulus[0-150], higher score indicate greater false alarm), response mean (average time spent to response to target stimulus [200-1100, low score means faster response to target stimulus]), Response (consistency of response time to target stimulus [30-650, Low score means good consistency of response]). (NCT01012622)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Omission:Baseline | Omission:Change at Week 12 | False alarm:Baseline | False alarm:Change at Week 12 | Response mean:Baseline | Response mean:Change at Week 12 | Response:Baseline | Response:Change at Week 12 | |
Osmotic Release Oral System (OROS) Methylphenidate HCL | 16.05 | -4.07 | 16.03 | -4.73 | 749.01 | -27.14 | 349.60 | -43.90 |
CAT was developed to properly reflect brain function in childhood. It provided measurement of simple inhibition-sustained attention in terms of omission(number of missing response to target stimulus [0-150], higher score indicate greater omission), false alarm(number of response to non-target stimulus [0-150], higher score indicate greater false alarm), response mean (average time spent to response to target stimulus [200-1100, low score means faster response to target stimulus]), Response (consistency of response time to target stimulus [30-650, Low score means good consistency of response]). (NCT01012622)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Omission:Baseline | Omission:Change at Week 12 | False alarm:Baseline | False alarm:Change at Week 12 | Response mean:Baseline | Response mean:Change at Week 12 | Response:Baseline | Response:Change at Week 12 | |
Osmotic Release Oral System (OROS) Methylphenidate HCL | 35.78 | -20.39 | 27.73 | -7.54 | 576.55 | -34.44 | 273.78 | -66.85 |
CAT was developed to properly reflect brain function in childhood. It provided measurement of simple interference-selective attention in terms of omission(number of missing response to target stimulus[0-150], higher score indicate greater omission), false alarm(number of response to non-target stimulus[0-150], higher score indicate greater false alarm), response mean (average time spent to response to target stimulus [200-1100, low score means faster response to target stimulus]), Response (consistency of response time to target stimulus [30-650, Low score means good consistency of response]). (NCT01012622)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Omission:Baseline | Omission:Change at Week 12 | False alarm:Baseline | False alarm:Change at Week 12 | Response mean:Baseline | Response mean:Change at Week 12 | Response:Baseline | Response:Change at Week 12 | |
Osmotic Release Oral System (OROS) Methylphenidate HCL | 20.39 | -10.83 | 26.03 | -6.14 | 648.48 | -54.35 | 276.74 | -72.18 |
K-ARS measures the 18 symptoms based on Diagnostic and Statistical Manual of Mental Disorders-forth edition (DSM-IV 1994). Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often), whereas the rating of 2 points or more was regarded as abnormal. Total scores range from 0 (no symptoms) to 54 (highly symptomatic), higher score indicates worsening of condition. (NCT01012622)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline | Change at Week 12 | |
Osmotic Release Oral System (OROS) Methylphenidate HCL | 33.37 | -20.43 |
"Parenting Stress Index (PSI) was designed to assess parent or guardian child-rearing stress index on a 5-rating scale from never to very truly. Out of 30 items, 20 items are scored, being consisted of 8 child characteristics-related stress items; 9 parent-child interaction-related stress items; and 3 achievement expectation-related stress items. A possible total score ranges from 20 to 100; Increase in score indicates higher stress perceived by the parent." (NCT01012622)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline | Change at Week 12 | |
Osmotic Release Oral System (OROS) Methylphenidate HCL | 58.20 | -5.25 |
CAT was developed to properly reflect brain function in childhood. It provided measurement of simple visual selective attention in terms of omission (number of missing response to target stimulus [0-150], higher score indicate greater omission), false alarm (number of response to non-target stimulus [0-150], higher score indicate greater false alarm), response mean (average time spent to response to target stimulus [200-1100, low score means faster response to target stimulus]), Response (consistency of response time to target stimulus [30-650, Low score means good consistency of response]). (NCT01012622)
Timeframe: Baseline and Week 12
Intervention | units on a scale (Mean) | |||||||
---|---|---|---|---|---|---|---|---|
Omission:Baseline | Omission:Change at Week 12 | False alarm:Baseline | False alarm:Change at Week 12 | Response mean:Baseline | Response mean:Change at Week 12 | Response:Baseline | Response:Change at Week 12 | |
Osmotic Release Oral System (OROS) Methylphenidate HCL | 8.79 | -4.53 | 17.42 | -5.03 | 501.32 | -37.41 | 201.05 | -48.36 |
CAT was developed to properly reflect brain function in childhood. The test battery provided a comprehensive measurement of simple visual auditory attention, interventional visual-auditory selective attention, divided attention, continuous attention, and operational memory. Working memory forward was measured in terms of width of space and number of correct responses ranging from 0 to 10. For width of space boxes were presented on the screen and participants remembered the order of presented box. Participants pressed the box using mouse in the backward order. Maximum number that participants correctly memorized box in the screen in the respective order was reported and overall number of times a participant responded correctly was also reported. (NCT01012622)
Timeframe: Baseline and Week 12
Intervention | correct responses (Mean) | |||
---|---|---|---|---|
Baseline:Number of correct responses | Change at Week 12:Number of correct responses | Baseline:Spatial span | Change at Week 12:Spatial span | |
Osmotic Release Oral System (OROS) Methylphenidate HCL | 4.22 | 1.86 | 3.63 | 1.24 |
CAT was developed to properly reflect brain function in childhood. The test battery provided a comprehensive measurement of simple visual auditory attention, interventional visual-auditory selective attention, divided attention, continuous attention, and operational memory. Working memory forward was measured in terms of width of space and number of correct responses ranging from 0 to 10. For width of space boxes were presented on the screen and participants remembered the order of presented box. Participants pressed the box using mouse in the forward order. Maximum number that participants correctly memorized box in the screen in the respective order was reported and overall number of times a participant responded correctly was also reported. (NCT01012622)
Timeframe: Baseline and Week 12
Intervention | correct responses (Mean) | |||
---|---|---|---|---|
Baseline:Number of correct responses | Change at Week 12:Number of correct responses | Baseline:Width of space | Change at Week 12:Width of space | |
Osmotic Release Oral System (OROS) Methylphenidate HCL | 5.76 | 0.63 | 4.46 | 0.25 |
The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse. Improved very much, Improved much and Improved a little are defined as improvement and No change, Aggravated a little, Aggravated much and Aggravated very much were defined as aggravation. (NCT01012622)
Timeframe: Week 12
Intervention | participants (Number) | |
---|---|---|
Improvement | Aggravation | |
Osmotic Release Oral System (OROS) Methylphenidate HCL | 122 | 7 |
7 reviews available for methylphenidate and Genetic Predisposition
Article | Year |
---|---|
Attention-deficit hyperactivity disorder (ADHD): an updated review of the essential facts.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Child; Child Behavior Disorders; Child Develop | 2014 |
[Attention deficit hyperactivity disorder].
Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System St | 2009 |
[Diagnostic validity of attention deficit/hyperactivity disorder: from phenomenology to neurobiology (II)].
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Cognition; Diagnosti | 2012 |
[Diagnostic and therapeutic update in narcolepsy].
Topics: Adolescent; Adult; Age of Onset; Animals; Autoimmune Diseases; Benzhydryl Compounds; Cataplexy; Chil | 2012 |
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Topics: Adult; Appetite Depressants; Attention Deficit Disorder with Hyperactivity; Bone Morphogenetic Prote | 2003 |
Attention-deficit/hyperactivity disorder in adults: an overview.
Topics: Adult; Age Factors; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; | 2000 |
Stimulant effects in attention deficit hyperactivity disorder: theoretical and empirical issues.
Topics: Adolescent; Animals; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2001 |
4 trials available for methylphenidate and Genetic Predisposition
Article | Year |
---|---|
Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dopamine Upt | 2016 |
COMT Val108/158Met polymorphism and the modulation of task-oriented behavior in children with ADHD.
Topics: Amino Acid Substitution; Attention Deficit Disorder with Hyperactivity; Catechol O-Methyltransferase | 2008 |
Val/Val genotype of brain-derived neurotrophic factor (BDNF) Val⁶⁶Met polymorphism is associated with a better response to OROS-MPH in Korean ADHD children.
Topics: Administration, Oral; Age Factors; Analysis of Variance; Attention Deficit Disorder with Hyperactivi | 2011 |
Genetic evidence for the association of the hypothalamic-pituitary-adrenal (HPA) axis with ADHD and methylphenidate treatment response.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Dexamethasone; Doubl | 2013 |
8 other studies available for methylphenidate and Genetic Predisposition
Article | Year |
---|---|
Genetic imaging study with [Tc-
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Brain; Brain Mapping; Central Nervous Sys | 2018 |
NK1 (TACR1) receptor gene 'knockout' mouse phenotype predicts genetic association with ADHD.
Topics: Animals; Attention Deficit Disorder with Hyperactivity; Base Sequence; Case-Control Studies; Corpus | 2010 |
[Dyslexia: a disease, a disorder or something else?].
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dyslexia; G | 2009 |
GIT1 is associated with ADHD in humans and ADHD-like behaviors in mice.
Topics: Adaptor Proteins, Signal Transducing; Amphetamine; Animals; Attention Deficit Disorder with Hyperact | 2011 |
A cooperative interaction between LPHN3 and 11q doubles the risk for ADHD.
Topics: Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Brain; Case-Control Studies; Choline; | 2012 |
Possible effect of norepinephrine transporter polymorphisms on methylphenidate-induced changes in neuropsychological function in attention-deficit hyperactivity disorder.
Topics: Adolescent; Alleles; Attention; Attention Deficit Disorder with Hyperactivity; Child; Female; Gene F | 2012 |
Transgenic mice expressing a human mutant beta1 thyroid receptor are hyperactive, impulsive, and inattentive.
Topics: Age Factors; Analysis of Variance; Animals; Attention; Attention Deficit Disorder with Hyperactivity | 2006 |
Ritalin: mom's little helper. A disorder long linked to sons migrates up the family tree.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Female; Genetic Predisposition to Disea | 2001 |